Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Viracta Therapeutics Inc (VIRX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Viracta Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.8499 +0.0021    +0.25%
17:57:03 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 36,763
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.8301 - 0.9000
Viracta Therapeutics 0.8499 +0.0021 +0.25%

Viracta Therapeutics Inc Company Profile

 
Get an in-depth profile of Viracta Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

40

Equity Type

ORD

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

Contact Information

Address 2533 South Coast Highway 101 Suite 210
Cardiff, 92007
United States
Phone 858 400 8470
Fax -

Top Executives

Name Age Since Title
Douglas V. Faller - - Scientific Founder & Chairman of Scientific Advisory Board
Ivor Royston 78 2007 Director
Thomas Eric Darcy 73 2021 Independent Director
Stephen Rubino 66 2021 Independent Director
Barry J. Simon 59 2021 Independent Director
Mark Andrew Rothera 61 2022 CEO, President & Director
Roger James Pomerantz 67 2020 Independent Chairman of the Board
Robert Baiocchi - 2018 Member of Scientific Advisory Board
Ronald Levy - 2018 Member of Scientific Advisory Board
Jane F. Barlow 63 2021 Independent Director
Daniel Douglas Von Hoff 76 - Member of Scientific Advisory Board
Lawrence S. Young - 2018 Member of Scientific Advisory Board
Pierluigi Porcu - 2018 Member of Scientific Advisory Board
Flavia Borellini 65 2021 Independent Director
Samuel Lafayette Murphy 46 2019 Independent Director
Carl H. June 70 2018 Member of Scientific Advisory Board
Gavin Giovannoni - 2024 Member of Scientific Advisory Board
Shannon Kenney - - Member of Scientific Advisory Board
Jane Chung 52 2022 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VIRX Comments

Write your thoughts about Viracta Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email